CNS Pharmaceuticals Inc (CNSP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CNS Pharmaceuticals Inc (CNSP) has a cash flow conversion efficiency ratio of -0.675x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($4.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CNS Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how CNS Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CNSP total liabilities for a breakdown of total debt and financial obligations.
CNS Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CNS Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blaize Holdings, Inc. Warrants
NASDAQ:BZAIW
|
-0.507x |
|
Oakajee Corporation Ltd
AU:OKJ
|
-0.189x |
|
CC Japan Income and Growth Trust PLC
LSE:CCJI
|
-0.007x |
|
Spectur Ltd
AU:SP3
|
-0.224x |
|
Avricore Health Inc
V:AVCR
|
-0.761x |
|
Aptose Biosciences Inc
TO:APS
|
0.381x |
|
RWS Holdings PLC
LSE:RWS
|
0.039x |
|
Cosmo Metals Ltd
AU:CMO
|
-0.035x |
Annual Cash Flow Conversion Efficiency for CNS Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of CNS Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see CNSP stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.52 Million | $-13.81 Million | -3.054x | -10.22% |
| 2024-12-31 | $6.18 Million | $-17.11 Million | -2.771x | -186.84% |
| 2023-12-31 | $-4.43 Million | $-14.14 Million | 3.190x | +345.76% |
| 2022-12-31 | $8.13 Million | $-10.56 Million | -1.298x | +36.50% |
| 2021-12-31 | $6.62 Million | $-13.54 Million | -2.045x | -289.68% |
| 2020-12-31 | $13.95 Million | $-7.32 Million | -0.525x | -12.23% |
| 2019-12-31 | $7.60 Million | $-3.55 Million | -0.467x | -135.85% |
| 2018-12-31 | $-549.30K | $-716.38K | 1.304x | -31.96% |
| 2017-12-31 | $-58.53K | $-112.20K | 1.917x | -- |
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate ca… Read more